Xylem fell 32.0% from $140.99 to $95.93, behind the S&P 500's +11.2%. Its worst day was Oct 27 (−14.2%), and its low came Oct 28 at $88.23.
Story events cover the past 12 months · Times ET
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Xylem closed at its highest level of the year, 3.6% above where the year started.
+0.9% · S&P 500 −0.1%
EPS of $1.42 beat the $1.41 estimate on $2.4B revenue (est. $2.4B); FY revenue guidance of $9.1B–$9.2B against the $9.3B consensus.
−8.0% · S&P 500 −0.3%
EPS of $1.12 beat the $1.08 estimate on $2.1B revenue (est. $2.1B); FY revenue guidance of $9.2B–$9.3B against the $9.2B consensus.
−4.5% · S&P 500 −0.5%
EPS of $1.46 beat the $1.34 estimate on $2.3B revenue (est. $2.3B); Q3 revenue guidance of $2.3B against the $2.3B consensus.
+4.0% · S&P 500 +0.2%
Xylem shares fell 5.5%, while the S&P 500 fell 0.1%.
−5.5% · S&P 500 −0.1%
EPS of $1.44 missed the $1.45 estimate on $2.2B revenue (est. $2.3B); Q4 revenue guidance of $2.3B against the $2.4B consensus.
−14.2%, the year's worst day · S&P 500 +0.6%
Xylem shares rose 5.0%, while the S&P 500 rose 1.7%.
+5.0% · S&P 500 +1.7%
Where it ended: a close of $95.93 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 9, 2027 (EPS est. $1.42, revenue est. $2.3B).
